Background According to interim findings of a phase II trial, the combination of INO-5401, a T-cell–activating immunotherapy and INO-9012, an immune activator of a different kind with Libtayo (Cemiplimab, a…
Background There is significant unmet medical need following treatment with Herceptin, Perjeta and Kadcyla in patients with metastatic HER2-positive breast cancer. In the HER2CLIMB trial, the addition of tucatinib to…
This time, we'll start from the end... Results of the study First of all, it is important to note that the research goals were not achieved in the entire study…
Many small cell lung cancer patients rapidly relapse due to the aggressive nature of the disease. While the current standard of care in the second-line setting can extend survival, treatment…
The Food and Drug Administration, the FDA, has granted capmatinib a “breakthrough therapy” designation as a first-line treatment for Non-Small Cell Lung Cancer (NSCLC) patients with MET mutation, EGFR Wild-type…
The main therapeutic objectives in treating metastatic disease are prolonging life (also called “Survival”) and Quality of Life (QoL), knowing the disease will stay in the body for life. ***…
Background The National Comprehensive Cancer Network, NCCN, is the health body which sets the world guidelines in treating cancer. The NCCN recommends clinical trials as the preferred option over current…
Don't miss opportunities to get drugs like this in a clinical trial setting! Why? Lurbinectedin monotherapy as a second-line therapy in patients with small cell lung cancer, SCLC, elicited a…
Background Bempegaldesleukin, NKTR-214, and nivolumab, Opdivo, was granted breakthrough deisgnation by the FDA for the first line treatment of patients with previously untreated unresectable or metastatic melanoma. Bempegaldesleukin, NKTR-214, is…
Background Pancreatic cancer is one of the most challenging types of cancer to treat, but new therapy using the body’s own immune system is providing new hope. Researchers at Baylor…